

Pepper Hamilton LLP
Attorneys at Law

RECEIVED
CENTRAL FAX CENTER

AUG 06 2004

OFFICIAL

50th Floor
500 Grant Street
Pittsburgh, PA 15219-2502
412.454.5000
Fax 412.281.0717
www.pepperlaw.com

FAX INFORMATION SHEET

Date: August 6, 2004
ID Number: 61297
Identifier: 112911.01701

<u>Recipient's Name</u>	<u>Company</u>	<u>General Number</u>	<u>Fax Number</u>
USPTO			703-872-9306

Sender: Raymond A. Miller **RETURN FAX TO K. PUJOL**
 Sender's Direct Line: 412-454-5813
 Sender's Email Address: Millerra@pepperlaw.com

Total Pages Including Cover: **19**

Comments: Please see attached RESPONSE TO RESTRICTION REQUIREMENT for U.S. Serial No. 09/965,967 and a Supplemental Information Disclosure Statement for U.S. Serial No. 09/965,967.

An original or a copy has [] or has not [] been sent to you by mail [] or by overnight service [] or by email [].

♦ ♦ If total pages are not received, or an error occurred during this transmission,
 please call the sender at the direct line listed above. ♦ ♦

♦ ♦ CONFIDENTIALITY NOTE ♦ ♦

The documents accompanying this facsimile transmission contain information from the law firm of Pepper Hamilton LLP which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this faxed information is strictly prohibited, and that the documents should be returned to this Firm immediately. In this regard, if you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us at no cost to you.

Operator's Use Only					
Start Time:	:	am [] pm []	End Time:	:	am [] pm []
Operator:					

Coversheet Page 1 of 1

PTO/SB/17 (10-03)

Approved for use through 07/31/2008, OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 55.00)

Complete if Known

Application Number	09/965,967
Filing Date	September 28, 2001
First Named Inventor	Shi
Examiner Name	Wax
Art Unit	1653
Attorney Docket No.	112911.01701

METHOD OF PAYMENT (check all that apply)

 Check Credit card Money Order Other None
 Deposit Account:

Deposit Account Number	50-0436
Deposit Account Name	Pepper Hamilton LLP

The Director is authorized to: (check all that apply)

 Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) or any underpayment of fee(s)
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity	Fee Code (\$)	Small Entity	Fee Code (\$)	Fee Description	Fee Paid
1001	770	2001	365	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	365	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1) (\$)					

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Independent Claims	Multiple Dependent	Extra Claims below	Fee from	Fee Paid
			-20* =	X	
			- 5** =	X	

Large Entity	Small Entity	Fee Description
1202	18	2202 9 Claims in excess of 20
1201	88	2201 43 Independent claims in excess of 3
1203	290	2203 145 Multiple dependent claim, if not paid
1204	88	2204 43 ** Reissue independent claims over original patent
1205	18	2205 9 ** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2) (\$)		

**or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description	Fee Paid
1051	130	2051 65 Surcharge - late filing fee or oath	
1052	50	2052 25 Surcharge - late provisional filing fee or cover sheet	
1053	130	1053 130 Non-English specification	
1812	2,520	1812 2,520 For filing a request for ex parte reexamination	
1804	920*	1804 920* Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805 1,840* Requesting publication of SIR after Examiner action	
1251	110	2251 55 Extension for reply within first month	
1252	420	2252 210 Extension for reply within second month	
1253	950	2253 475 Extension for reply within third month	
1254	1,480	2254 740 Extension for reply within fourth month	
1265	2,010	2255 1,005 Extension for reply within fifth month	
1401	330	2401 165 Notice of Appeal	
1402	330	2402 165 Filing a brief in support of an appeal	
1403	280	2403 145 Request for oral hearing	
1451	1,510	1451 1,510 Petition to institute a public use proceeding	
1452	110	2452 65 Petition to revive - unavoidable	
1453	1,330	2453 665 Petition to revive - unintentional	
1501	1,330	2501 665 Utility issue fee (or release)	
1502	480	2502 240 Design issue fee	
1503	640	2503 320 Plant issue fee	
1460	130	1460 130 Petitions to the Commissioner	
1807	50	1807 50 Processing fee under 37 CFR 1.17(q)	
1808	180	1808 180 Submission of Information Disclosure Stmt	
8021	40	8021 40 Recording each patent assignment per property (times number of properties)	
1809	770	2809 385 Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810 385 For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801 386 Request for Continued Examination (RCE)	
1802	900	1802 900 Request for expedited examination of a design application	
Other fee (specify)			
Reduced by Basic Filing Fee Paid		SUBTOTAL (3) (\$)	55.00

(Complete if applicable)

Name (Print/Type)	Raymond A. Miller	Registration No. (Attorney/Agent)	42,891	Telephone	412.454.5000
Signature	<i>Raymond A. Miller</i>			Date	August 6, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Attorney Docket No. 112911.01701

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED**CENTRAL FAX CENTER**

In re Application of:

AUG 06 2004

Shi, et al.

Serial No. 09/965,967 : Group Art Unit: 1653

Filed: September 28, 2001 : Examiner: Wax, Robert, A.

For: COMPOSITIONS FOR PROMOTING APOPTOSIS

OFFICIAL**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents
Box Non-Fee Amendment
P.O. Box 1450
Alexandria, VA 22313-1450

This is a response to a restriction requirement mailed in the Office Action dated June 28, 2004 in the above identified application submitted herewith is a one (1) month extension, extending the period to respond to August 28, 2004. Pursuant to a telephone conference with the Examiner on Tuesday August 3, 2003, the Examiner rejoined the invention designated as Invention I (Claims 1-12 and 18-22) and Invention II (Claims 13-17). Accordingly, Applicant's restriction election is timely filed and fully responsive to the restriction requirement.

Accordingly, Applicant provisionally elects claims 1-22 with traverse.

ATTORNEY DOCKET NO. 112911.01701

PATENT

CLAIMS

1. (Original) A synthetic tetrapeptide that binds an Inhibitor of Apoptosis Protein (IAP) and relieves IAP-mediated inhibition of caspase activity, wherein the tetrapeptide binds a surface groove within a BIR domain of the IAP.
2. (Original) The synthetic tetrapeptide of claim 1, wherein the BIR domain is a BIR 2 domain or a BIR3 domain.
3. (Original) The synthetic tetrapeptide of claim 1, having an amino acid sequence the same as an N-terminal sequence of a cellular IAP-binding protein.
4. (Original) The synthetic tetrapeptide of claim 3, wherein the cellular IAP-binding protein is a mammalian protein or a Drosophila protein.
5. (Original) The synthetic tetrapeptide of claim 1, having a sequence X1-X2-X3-X4 (SEQ ID NO:29), wherein

X1 is A

X2 is V, T or I,

X3 is P or A, and

X4 is F, Y, I or V.

6. (Original) The synthetic tetrapeptide of claim 5, selected from the group consisting of AVPI (SEQ ID NO:1), AVAF (SEQ ID NO:2); AIAY (SEQ ID NO:3), AVPF (SEQ ID NO:4), ATPF (SEQ ID NO:5), AVPY (SEQ ID NO:6) and ATPV (SEQ ID NO:7).
7. (Original) The synthetic tetrapeptide of claim 6, which is AVPF (SEQ ID NO:4).
8. (Original) A synthetic peptide that binds IAP and relieves IAP-mediated inhibition of caspase activity, comprising the tetrapeptide of claim 1 and a C-terminal extension of one or more of up to three additional amino acid residues comprising a sequence the same as a sequence of a cellular IAP-binding protein in residues 5-7 of its N-terminus.
9. (Original) The synthetic peptide of claim 8, selected from the group consisting of:
 - (i) a pentapeptide wherein the C-terminal amino acid is Y or F;
 - (ii) a hexapeptide comprising the pentapeptide of (i) and a C-terminal amino acid which is L or I;
 - (iii) a heptapeptide comprising the hexapeptide of (ii) and a C-terminal P.

ATTORNEY DOCKET NO. 112911.01701

PATENT

10. (Original) The synthetic peptide of claim 9, having a sequence selected from the group consisting of AVAFYIP (SEQ ID NO:9), AIAYFLP (SEQ ID NO:10) and AVPFYLP (SEQ ID NO:11).
11. (Original) A non-peptide or partial peptide mimetic of the synthetic tetrapeptide of claim 3.
12. (Original) A non-peptide or partial peptide mimetic of the synthetic peptide of claim 8.
13. (Original) A method of stimulating apoptosis in a cell, comprising administering to the cell the synthetic tetrapeptide of claim 1, in an amount sufficient to stimulate the apoptosis in the cell.
14. (Original) The method of claim 13, wherein the cell is a cultured cell.
15. (Original) The method of claim 13, wherein the cell is disposed within a living organism.
16. (Original) The method of claim 15, wherein the organism is a mammal.
17. (Original) The method of claim 16, wherein the mammal is a human.
18. (Original) A compound that binds an Inhibitor of Apoptosis Protein (IAP) and relieves IAP-mediated inhibition of caspase activity, the compound having a formula R1-R2-R3-R4, wherein

R1 is A or a mimetic of A;
R2 is V, T or I, or a mimetic of V, T or I;
R3 is P or A, or a mimetic of P or A; and
R4 is F, Y, I or V, or a mimetic of F, Y, I or V.

19. (Original) The compound of claim 18, which is a non-peptide or partial peptide mimetic of an amino acid sequence selected from the group consisting of AVPI (SEQ ID NO:1), AVAF (SEQ ID NO:2); AIAY (SEQ ID NO:3), AVPF (SEQ ID NO:4), ATPF (SEQ ID NO:5), AVPY (SEQ ID NO:6) and ATPV (SEQ ID NO:7).
20. (Original) The compound of claim 19, which is a non-peptide or partial peptide mimetic of amino acid sequence AVPF (SEQ ID NO:4).
21. (Original) A compound that binds an Inhibitor of Apoptosis Protein (IAP) and relieves IAP-mediated inhibition of caspase activity, the compound having a formula R1-R2-R3-R4-R5-R6-R7, wherein

ATTORNEY DOCKET NO. 112911.01701

PATENT

R1 is A or a mimetic of A;
R2 is V, T or I, or a mimetic of V, T or I;
R3 is P or A, or a mimetic of P or A; and
R4 is F, Y, I or V, or a mimetic of F, Y, I or V;
R5 is missing, or is Y or F, or a mimetic of Y or F;
R6 is present only if R5 is present, and is L or I, or a mimetic of L or I;

and

R7 is present only if R5 and R6 are present, and is P or a mimetic of P.

22. (Original) The compound of claim 21, comprising a partial peptide or non-peptide mimetic of an amino acid sequence selected from the group consisting of AVAFYIP (SEQ ID NO:9), ALAYFLP (SEQ ID NO:10) and AVPFYLP (SEQ ID NO:11).

23. (Withdrawn) A method of making a drug suitable for treating cell proliferative disease in a mammal by promoting apoptosis in proliferatively diseased cells, the method comprising:

a) constructing a compound that binds a mammalian IAP and relieves IAP-mediated inhibition of caspase activity, wherein the compound binds a surface groove within a BIR3 domain of the IAP; and

b) determining whether the compound promotes apoptosis in a proliferatively diseased cell, an affirmative determination indicating that the drug is suitable for treating the cell proliferative disease.

24. (Withdrawn) The method of claim 23, wherein the cell proliferative disease is cancer.

25. (Withdrawn) The method of claim 23, wherein the compound constructed is a partial peptide or non-peptide mimetic of a tetrapeptide having an amino acid sequence the same as an N-terminal sequence of a cellular IAP-binding protein.

26. (Withdrawn) A method of screening for a compound that binds an IAP at a surface groove within a BIR domain, the method comprising:

a) providing a synthetic tetrapeptide that binds a selected IAP and relieves IAP-mediated inhibition of caspase activity, wherein the tetrapeptide binds a surface groove within a BIR domain of the IAP;

b) combining the tetrapeptide and the IAP in the presence of a test compound under conditions wherein, in the absence of the test compound, a pre-determined quantity of the tetrapeptide would bind the IAP; and

ATTORNEY DOCKET NO. 112911.01701

PATENT

c) determining if the quantity of the tetrapeptide bound to the IAP is decreased in the presence of the test compound, the decrease being indicative that the test compound binds the IAP and relieves IAP-mediated inhibition of caspase activity.

27. (Withdrawn) The method of claim 26, which further comprises the step of determining if the test compound modulates IAP-mediated inhibition of caspase activity.

28. (Withdrawn) The method of claim 27, wherein the modulating comprises relieving IAP-mediated inhibition of caspase activity.

29. (Withdrawn) The method of claim 27, wherein the modulating comprises promoting IAP-mediated inhibition of caspase activity.

30. (Withdrawn) The method of claim 26, which further comprises the step of determining if the test compound modulates cellular apoptosis.

31. (Withdrawn) The method of claim 30, wherein the modulating comprises promoting apoptosis.

32. (Withdrawn) The method of claim 30, wherein the modulating comprises inhibiting apoptosis.

ATTORNEY DOCKET NO. 112911.01701

PATENT

REMARKS

In the Office action dated June 28, 2004, the Examiner required restriction of the claims as follows (i) Invention I, claims 1-12 and 18-22, drawn to synthetic tetrapeptide or mimetic; (ii) Invention II, claims 13-17, drawn to a method of stimulating apoptosis, (iii) Invention III, claims 23-25 drawn to a method of making a drug suitable for treating cell proliferative disease in a mammal by promoting apoptosis in proliferatively diseased cells which includes an assay for apoptosis-inducing activity; and (iv) Invention IV, claims 26-32, drawn to a method of screening for a compound that binds IAP. In the telephone conference of August 3, 2004 the Examiner agreed that the restriction between Groups I and II was improper, however, he maintained the restriction requirement between the rejoined Group I and II and Invention Groups III and IV.

Applicant respectfully traverses the remaining restriction requirement and respectfully requests reconsideration. In order to be fully responsive, Applicant has provisionally elected, with traverse, the invention defined by claims 1-22. By this election, Applicant does not admit, nor does Applicant waive the right to argue against at a later date, the Examiner's statement that the groups of inventions are patentably distinct. Applicant expressly reserves the right to present the claims of Invention Groups III or IV, or other claims, in one or more divisional, continuation, or continuation-in-part applications at a later date.

Applicant does not believe that the Examiner would be seriously burdened by a search for each of Groups I-IV since the subject matter of the search for the claims of Group I and Group II would greatly overlap, if not be identical, to the search for the claims of Group III and Group IV. A search for Groups I and II of the tetrapeptide itself would necessarily include the methods of Group III and Group IV.

Applicant appreciates the Examiner rejoining Invention Group I and Invention Group II. In view of the above election and remarks, Applicant believes that the restriction requirement is inappropriate. Favorable resolution is respectfully requested.


This response has been timely filed. Accordingly, no additional fee is required. In the event that an additional fee is required for this response, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-0436.

ATTORNEY DOCKET NO. 112911.01701

PATENT

Should the Examiner have any questions or comments, or need any additional information from Applicant's attorney, he is invited to contact the undersigned at his convenience.

Respectfully submitted,



By:

Raymond A. Miller
Reg. No. 42,891

Dated: August 6, 2004

PEPPER HAMILTON LLP
500 Grant Street
One Mellon Bank Center, 50th Floor
Pittsburgh, PA 15219
(412) 454-5813
(412) 281-0717 - facsimile